Pharmaceutical Executive-12-01-2020

Vaccine strides, likely pricing impasse point to optimism for 2021.

How the pandemic’s impact on physicians and patients has spurred fundamental changes and redefined approaches in areas such as adherence and drug formulation and delivery.

The pandemic has raised the stakes for companies pursuing new data-harnessing capabilities in contract management and KPI benchmarking and tracking.

Adoption of digital by biopharma reps has added an element of flexibility to their engagement strategies, resulting in better communications with HCPs.

How the CIO role has transformed and strengthened against the backdrop of COVID-19.

A look at the leadership themes that have resonated most in 2020.

Must find common ground between digitalization and protection laws.

The redirection of healthcare and life sciences resources to COVID-19 has taken focus from other areas of need, including antimicrobial resistance.

2020 has proven to be a year like no other for pharma. Here is a quick look back at some of the trends 2020 created for the industry.

Amid COVID-19, pressure for “socially responsible” pricing could temper investments in future urgent healthcare needs.

Pandemic requires innovative R&D and regulatory flexibility to generate critical vaccines and therapies.

Why major companies are stepping up environmental commitments.

Click the title above for a link to open the Pharmaceutical Executive December 2020 issue in an interactive PDF format.

Samit Hirawat, chief medical officer at Bristol Myers Squibb, talks about his leading role in BMS’ $300M, five-year plan to expand its efforts in health equity and his career-long commitment to putting patients first.

To realize the promise of genomics, pharma must be prepared to mine the data more effectively.

Recent roundtable brought together by Pharm Exec and Parexel features insights from leaders in the pharma industry on the current state and future of RWE.